This Week in BMC Cancer

Premium

In BMC Cancer this week, researchers in Kansas and Oklahoma describe the development and characterization of a novel C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. Hsp90 has been shown to be over-expressed in a number of cancers, the authors write. For this study, the team used PC3-MM2 and LNCaP-LN3 prostate cancer cell lines to test an Hsp90 inhibitor, KU174.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.